Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevalence and Spectrum of BRCA Germline Variants in Central Italian High Risk or Familial Breast/Ovarian Cancer Patients: A Monocentric Study.
Foglietta J, Ludovini V, Bianconi F, Pistola L, Reda MS, Al-Refaie A, Tofanetti FR, Mosconi A, Minenza E, Anastasi P, Molica C, Stracci F, Roila F. Foglietta J, et al. Among authors: mosconi a. Genes (Basel). 2020 Aug 12;11(8):925. doi: 10.3390/genes11080925. Genes (Basel). 2020. PMID: 32806537 Free PMC article.
Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long-term results.
Colozza M, Gori S, Mosconi AM, Anastasi P, de Angelis V, Giansanti M, Mercati U, Aristei C, Latini P, Tonato M. Colozza M, et al. Among authors: mosconi am. Am J Clin Oncol. 1996 Feb;19(1):10-7. doi: 10.1097/00000421-199602000-00003. Am J Clin Oncol. 1996. PMID: 8554028 Clinical Trial.
Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study.
Cocconi G, Bisagni G, Bella M, Acito L, Anastasi P, Carpi A, Di Costanzo F, Frassoldati A, Mosconi A, Borrini A, Buzzi P. Cocconi G, et al. Among authors: mosconi a. Am J Clin Oncol. 1999 Dec;22(6):593-600. doi: 10.1097/00000421-199912000-00010. Am J Clin Oncol. 1999. PMID: 10597744 Clinical Trial.
Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients.
Ludovini V, Sidoni A, Pistola L, Bellezza G, De Angelis V, Gori S, Mosconi AM, Bisagni G, Cherubini R, Bian AR, Rodinò C, Sabbatini R, Mazzocchi B, Bucciarelli E, Tonato M, Colozza M. Ludovini V, et al. Among authors: mosconi am. Breast Cancer Res Treat. 2003 Sep;81(2):159-68. doi: 10.1023/a:1025755717912. Breast Cancer Res Treat. 2003. PMID: 14572158
Cancer of the penis.
Mosconi AM, Roila F, Gatta G, Theodore C. Mosconi AM, et al. Crit Rev Oncol Hematol. 2005 Feb;53(2):165-77. doi: 10.1016/j.critrevonc.2004.09.006. Crit Rev Oncol Hematol. 2005. PMID: 15661566 Review.
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.
Lorusso D, Scambia G, Pignata S, Sorio R, Amadio G, Lepori S, Mosconi A, Pisano C, Mangili G, Maltese G, Sabbatini R, Artioli G, Gamucci T, Di Napoli M, Capoluongo E, Ludovini V, Raspagliesi F, Ferrandina G. Lorusso D, et al. Among authors: mosconi a. Ann Oncol. 2016 Mar;27(3):487-93. doi: 10.1093/annonc/mdv608. Epub 2015 Dec 17. Ann Oncol. 2016. PMID: 26681678 Free article. Clinical Trial.
Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
Artioli G, Giannone G, Valabrega G, Maggiorotto F, Genta S, Pignata S, Lorusso D, Cormio G, Scalone S, Nicoletto MO, Greco F, Rossi E, Spagnoletti I, De Giorgi U, Orditura M, Mosconi AM, Kardhashi A, Bogliolo S, Borgato L. Artioli G, et al. Among authors: mosconi am. Gynecol Oncol. 2021 Jun;161(3):755-761. doi: 10.1016/j.ygyno.2021.04.014. Epub 2021 Apr 20. Gynecol Oncol. 2021. PMID: 33888336 Free article.
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators. Geyer CE Jr, et al. Ann Oncol. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10. Ann Oncol. 2022. PMID: 36228963 Free PMC article. Clinical Trial.
64 results